80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

FOR IMMEDIATE RELEASE

QT Vascular Announces Issue of Key Patent in Japan

- PTA Patent for Glider™ PTCA balloon reflects progression of company's Asian growth strategy
- Group to leverage on growing ageing population in Japan and Asia with expansion of patent portfolio
- Asian operations to experience strong growth from positive order momentum with respect to Glider family of products in 4Q2014 and additional regulatory approvals for Chocolate® in 2015

Singapore, 26 August 2014 – Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Japanese patent office issued its wholly owned US subsidiary, TriReme Medical LLC, a Japanese patent number 5580886 for its proprietary balloon technology relating to side branch balloon. Significant elements of this technology are used in the Group's Glider PTCA balloon catheter.

Glider is the world's only torqueable balloon containing unique patent-protected features that make it ideal for use in challenging coronary interventions. These include the combination of a torqueable shaft and a skived tip and an ultra short 4mm balloon length for the treatment of focal lesions and the ostium of side branches. Glider has demonstrated an ability to cross in cases where other balloons failed and were not able to complete the procedure. Glider has received regulatory approvals and is in commercial launch in numerous countries, including Japan, the United States, and Europe.

The continued adoption of the Glider family of products is expected to boost company sales in the region later this year. Sales from Asia in 2H14 are expected to have positive revenue contribution as the Group is scheduled to ship orders to China and Japan by 4Q14. Management expects this trend to continue as additional regulatory approvals in the Asia Pacific region are expected next year.

Over the last few decades, as healthcare and nutrition have improved in developed countries, life expectancies have also increased. This had led to the steady growth in the size of the over-65 year old population across Japan and Asia. As Coronary Artery Disease ("CAD") is more prevalent in the over-65 population, the largest demand driver for CAD treatments is the ageing population. The Group believes our products, such as Glider, offer compelling solutions for patients suffering from CAD.

Dr. Eitan Konstantino, the Group's Chief Executive Officer, commented, ***"The Japanese patent issued is a testimonial to the innovation power of the group. Patients in Asia Pacific and around the world deserve the best treatment options and our investments in innovation and development will secure our growth. Going forward, we expect to witness positive order momentum for our Glider products in Asia, while we continue to advance the regulatory approvals of Chocolate® in Asia Pacific, in line with plans to expand our future product pipeline."***

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

- End –

About Coronary Artery Disease

Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.

About QT Vascular Ltd.

QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

For more information, please refer to: http://www.qtvascular.com/

Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd
Kamal SAMUEL, kamal@financialpr.com.sg
Mark LIN, marklin@financialpr.com.sg
Tel: (65) 6438 2990 Fax: (65) 6438 0064

QTVascular

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.